Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · NovoNorm
NovoNorm 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-088411 · Präparat HOS-083643
Co-administration of trimethoprim (160 mg twice daily), a moderate CYP2C8 inhibitor, and
repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC, Cmax and t½ (1.6-fold, 1.4-fold
and 1.2-fold respectively) with no statistically significant effects on the blood glucose levels. This
lack of pharmacodynamic effect was observed with a sub-therapeutic dose of repaglinide. Since the
safety profile of this combination has not been established with dosages higher than 0.25 mg for
repaglinide and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide
should be avoided. If concomitant use is necessary, careful monitoring of blood glucose and close
clinical monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 756dfc81cfc3fd1b84695dac1157263ddedc8a5091e62e325aa530a037340687 · Zeichen 2075–2814 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-088413 · Präparat HOS-083643
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of
the metabolism of repaglinide. Seven days pre-treatment with rifampicin (600 mg), followed by co-
administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC
(effect of a combined induction and inhibition). When repaglinide was given 24 hours after the last
rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose
adjustment which should be based on carefully monitored blood glucose concentrations at both
initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and
induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of
rifampicin where the inductive effect of rifampicin is no longer present. It cannot be excluded that
other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John’s wort, may have a similar
effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) glucose (HOS-088412) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 31fab674d3b982b5678db881a9858bd54a43f38e2abad0b375f6a21302409319 · Zeichen 2816–3890 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-088414 · Präparat HOS-083643
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) glucose (HOS-088412) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 87f43c80efc4087eb3a239c087cbe51c7443c8eec3071c799c234a855ad41389 · Zeichen 3892–4891 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 5–6
HOS-088416 · Präparat HOS-083643
5
dose of 0.25 mg) and ciclosporin (repeated dose at 100 mg) increased repaglinide AUC and Cmax
about 2.5-fold and 1.8-fold respectively. Since the interaction has not been established with dosages
higher than 0.25 mg for repaglinide, the concomitant use of ciclosporin with repaglinide should be
avoided. If the combination appears necessary, careful clinical and blood glucose monitoring should
be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 4caebe7e15b1b5a732f7c285c5b7d822fd7d2515b90558cef35ef5d446e5558c · Zeichen 5045–5474 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-088417 · Präparat HOS-083643
In an interaction study with healthy volunteers, co-administration of deferasirox (30 mg/kg/day,
4 days), a moderate inhibitor of CYP2C8 and CYP3A4, and repaglinide (single dose, 0.5 mg) resulted
in an increase in repaglinide systemic exposure (AUC) to 2.3-fold (90% CI [2.03-2.63]) of control, a
1.6-fold (90% CI [1.42-1.84]) increase in Cmax, and a small, significant decrease in blood glucose
values. Since the interaction has not been established with dosages higher than 0.5 mg for repaglinide,
the concomitant use of deferasirox with repaglinide should be avoided. If the combination appears
necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): deferasirox (HOS-088409) glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 6228a5c573ae9e7d45a0c698714b708a58ce9257484bebb17d2647197f0db668 · Zeichen 5476–6169 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-088418 · Präparat HOS-083643
In an interaction study with healthy volunteers, co-administration of clopidogrel (300 mg loading
dose), a CYP2C8 inhibitor, increased repaglinide exposure (AUC0–∞) 5.1-fold and continued
administration (75 mg daily dose) increased repaglinide exposure (AUC0–∞) 3.9-fold. A small,
significant decrease in blood glucose values was observed. Since the safety profile of the co-treatment
has not been established in these patients, the concomitant use of clopidogrel and repaglinide should
be avoided. If concomitant use is necessary, careful monitoring of blood glucose and close clinical
monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glucose (HOS-088412) clopidogrel (HOS-087927)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 56d4dedf2afd90d365a5bce8e2c7892aaff5e60aebc849784f195feb2c6031de · Zeichen 6171–6807 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 1 mg tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-088446 · Präparat HOS-083643
Co-administration of trimethoprim (160 mg twice daily), a moderate CYP2C8 inhibitor, and
repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC, Cmax and t½ (1.6-fold, 1.4-fold
and 1.2-fold respectively) with no statistically significant effects on the blood glucose levels. This
lack of pharmacodynamic effect was observed with a sub-therapeutic dose of repaglinide. Since the
safety profile of this combination has not been established with dosages higher than 0.25 mg for
repaglinide and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide
should be avoided. If concomitant use is necessary, careful monitoring of blood glucose and close
clinical monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 756dfc81cfc3fd1b84695dac1157263ddedc8a5091e62e325aa530a037340687 · Zeichen 2076–2815 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 1 mg tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-088447 · Präparat HOS-083643
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of
the metabolism of repaglinide. Seven days pre-treatment with rifampicin (600 mg), followed by co-
administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC
(effect of a combined induction and inhibition). When repaglinide was given 24 hours after the last
rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose
adjustment which should be based on carefully monitored blood glucose concentrations at both
initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and
induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of
rifampicin where the inductive effect of rifampicin is no longer present. It cannot be excluded that
other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John’s wort, may have a similar
effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) glucose (HOS-088412) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 31fab674d3b982b5678db881a9858bd54a43f38e2abad0b375f6a21302409319 · Zeichen 2817–3891 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 1 mg tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-088448 · Präparat HOS-083643
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) glucose (HOS-088412) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 87f43c80efc4087eb3a239c087cbe51c7443c8eec3071c799c234a855ad41389 · Zeichen 3893–4892 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 1 mg tablets · Abschnitt 4.5 · PDF-Seite 15–16
HOS-088449 · Präparat HOS-083643
15
In a study conducted in healthy volunteers, the concomitant administration of repaglinide (a single
dose of 0.25 mg) and ciclosporin (repeated dose at 100 mg) increased repaglinide AUC and Cmax about
2.5-fold and 1.8-fold respectively. Since the interaction has not been established with dosages higher
than 0.25 mg for repaglinide, the concomitant use of ciclosporin with repaglinide should be avoided.
If the combination appears necessary, careful clinical and blood glucose monitoring should be
performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 2b2e9d14afc04b22cd028a46f51e069fb32546a2d81fd12af9f398f78e8105f8 · Zeichen 4946–5476 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 1 mg tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-088450 · Präparat HOS-083643
In an interaction study with healthy volunteers, co-administration of deferasirox (30 mg/kg/day,
4 days), a moderate inhibitor of CYP2C8 and CYP3A4, and repaglinide (single dose, 0.5 mg) resulted
in an increase in repaglinide systemic exposure (AUC) to 2.3-fold (90% CI [2.03-2.63]) of control, a
1.6-fold (90% CI [1.42-1.84]) increase in Cmax, and a small, significant decrease in blood glucose
values. Since the interaction has not been established with dosages higher than 0.5 mg for repaglinide,
the concomitant use of deferasirox with repaglinide should be avoided. If the combination appears
necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): deferasirox (HOS-088409) glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 6228a5c573ae9e7d45a0c698714b708a58ce9257484bebb17d2647197f0db668 · Zeichen 5478–6171 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 1 mg tablets · Abschnitt 4.5 · PDF-Seite 16
HOS-088451 · Präparat HOS-083643
In an interaction study with healthy volunteers, co-administration of clopidogrel (300 mg loading
dose), a CYP2C8 inhibitor, increased repaglinide exposure (AUC0–∞) 5.1-fold and continued
administration (75 mg daily dose) increased repaglinide exposure (AUC0–∞) 3.9-fold. A small,
significant decrease in blood glucose values was observed. Since the safety profile of the co-treatment
has not been established in these patients, the concomitant use of clopidogrel and repaglinide should
be avoided. If concomitant use is necessary, careful monitoring of blood glucose and close clinical
monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glucose (HOS-088412) clopidogrel (HOS-087927)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 56d4dedf2afd90d365a5bce8e2c7892aaff5e60aebc849784f195feb2c6031de · Zeichen 6173–6809 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 2 mg tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-088479 · Präparat HOS-083643
Co-administration of trimethoprim (160 mg twice daily), a moderate CYP2C8 inhibitor, and
repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC, Cmax and t½ (1.6-fold, 1.4-fold
and 1.2-fold respectively) with no statistically significant effects on the blood glucose levels. This
lack of pharmacodynamic effect was observed with a sub-therapeutic dose of repaglinide. Since the
safety profile of this combination has not been established with dosages higher than 0.25 mg for
repaglinide and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide
should be avoided. If concomitant use is necessary, careful monitoring of blood glucose and close
clinical monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 756dfc81cfc3fd1b84695dac1157263ddedc8a5091e62e325aa530a037340687 · Zeichen 2076–2815 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 2 mg tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-088480 · Präparat HOS-083643
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of
the metabolism of repaglinide. Seven days pre-treatment with rifampicin (600 mg), followed by co-
administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC
(effect of a combined induction and inhibition). When repaglinide was given 24 hours after the last
rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose
adjustment which should be based on carefully monitored blood glucose concentrations at both
initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and
induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of
rifampicin where the inductive effect of rifampicin is no longer present. It cannot be excluded that
other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John’s wort, may have a similar
effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) glucose (HOS-088412) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 31fab674d3b982b5678db881a9858bd54a43f38e2abad0b375f6a21302409319 · Zeichen 2817–3891 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 2 mg tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-088481 · Präparat HOS-083643
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) glucose (HOS-088412) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 87f43c80efc4087eb3a239c087cbe51c7443c8eec3071c799c234a855ad41389 · Zeichen 3893–4892 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 2 mg tablets · Abschnitt 4.5 · PDF-Seite 25–26
HOS-088482 · Präparat HOS-083643
25
In a study conducted in healthy volunteers, the concomitant administration of repaglinide (a single
dose of 0.25 mg) and ciclosporin (repeated dose at 100 mg) increased repaglinide AUC and Cmax about
2.5-fold and 1.8-fold respectively. Since the interaction has not been established with dosages higher
than 0.25 mg for repaglinide, the concomitant use of ciclosporin with repaglinide should be avoided.
If the combination appears necessary, careful clinical and blood glucose monitoring should be
performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 2242f0e96740c54ad01512e31aa204eca0d223b28f8562147cafe26c24e8db9c · Zeichen 4945–5475 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 2 mg tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-088483 · Präparat HOS-083643
In an interaction study with healthy volunteers, co-administration of deferasirox (30 mg/kg/day,
4 days), a moderate inhibitor of CYP2C8 and CYP3A4, and repaglinide (single dose, 0.5 mg) resulted
in an increase in repaglinide systemic exposure (AUC) to 2.3-fold (90% CI [2.03-2.63]) of control, a
1.6-fold (90% CI [1.42-1.84]) increase in Cmax, and a small, significant decrease in blood glucose
values. Since the interaction has not been established with dosages higher than 0.5 mg for repaglinide,
the concomitant use of deferasirox with repaglinide should be avoided. If the combination appears
necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): deferasirox (HOS-088409) glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 6228a5c573ae9e7d45a0c698714b708a58ce9257484bebb17d2647197f0db668 · Zeichen 5477–6170 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 2 mg tablets · Abschnitt 4.5 · PDF-Seite 26
HOS-088484 · Präparat HOS-083643
In an interaction study with healthy volunteers, co-administration of clopidogrel (300 mg loading
dose), a CYP2C8 inhibitor, increased repaglinide exposure (AUC0–∞) 5.1-fold and continued
administration (75 mg daily dose) increased repaglinide exposure (AUC0–∞) 3.9-fold. A small,
significant decrease in blood glucose values was observed. Since the safety profile of the co-treatment
has not been established in these patients, the concomitant use of clopidogrel and repaglinide should
be avoided. If concomitant use is necessary, careful monitoring of blood glucose and close clinical
monitoring should be performed (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glucose (HOS-088412) clopidogrel (HOS-087927)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 56d4dedf2afd90d365a5bce8e2c7892aaff5e60aebc849784f195feb2c6031de · Zeichen 6172–6808 im Abschnitt
Wechselwirkungen · Insuman
Insuman Rapid 40 IU/ml solution for injection in a vial Insuman Rapid 100 IU/ml solution for injection in a vial · Abschnitt 4.5 · PDF-Seite 5
HOS-088584 · Präparat HOS-083671
A number of substances affect glucose metabolism and may require dose adjustment of human insulin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): glucose (HOS-088412)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 4db2912b1904d5d7405ac531f7c49fb4f0cadae1b57c5afcdbc1b376702a91b3 · Zeichen 0–98 im Abschnitt
Wechselwirkungen · Insuman
Insuman Rapid 100 IU/ml solution for injection in a cartridge Insuman Rapid SoloStar 100 IU/ml solution for injection in a pre-filled pen · Abschnitt 4.5 · PDF-Seite 16
HOS-088612 · Präparat HOS-083671
A number of substances affect glucose metabolism and may require dose adjustment of human insulin.
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to
hypoglycaemia include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE)
inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline,
propoxyphene, salicylates and sulphonamide antibiotics.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): propoxyphene (HOS-086140) glucose (HOS-088412) pentoxifylline (HOS-088586) disopyramide (HOS-085595) fluoxetine (HOS-085946)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-05T14:48:00Z · SHA-256 361eee512a62ae9d440e9dc3368e92bfdf642f50b791ed122087c5b884c15e02 · Passage 0121d5df56b2a6e84d760a6414df4c03a5fcac4ba6433ca1c797ee593908d785 · Zeichen 0–443 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.